RT Journal Article
SR Electronic
T1 The bioavailability of compounded and generic rapamycin in normative aging individuals: A retrospective study and review with clinical implications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.12.24311432
DO 10.1101/2024.08.12.24311432
A1 Harinath, Girish
A1 Lee, Virginia
A1 Nyquist, Andy
A1 Moel, Mauricio
A1 Wouters, Maartje
A1 Hagemeier, Jesper
A1 Verkennes, Brandon
A1 Tacubao, Colleen
A1 Kauppi, Krister
A1 Morgan, Stefanie L.
A1 Isman, Anar
A1 Zalzala, Sajad
YR 2024
UL http://medrxiv.org/content/early/2024/08/16/2024.08.12.24311432.abstract
AB Rapamycin, also known as sirolimus, has demonstrated great potential for application in longevity medicine. However, the bioavailability of generic and compounded rapamycin at longevity doses in normative aging individuals remains unknown. We conducted a retrospective, real-world study determining the 24-hour blood rapamycin levels to establish the relative bioavailability, dose-to-blood level linearity and inter-individual heterogeneity in a normative aging cohort. Participants received either compounded rapamycin (n = 23, dosages 5, 10, or 15 mg) or generic rapamycin (n= 44, dosages 2, 3, 6, or 8 mg) once per week, and were asked to obtain a sirolimus level blood draw 24 hours after dose self-administration. Similar blood rapamycin levels and a linear dose-to-blood level relationship were observed for both formulations, although a higher bioavailability per milligram of rapamycin was noted for the generic formulation (compounded averaged 0.287 (28.7%) bioavailability relative to generic rapamycin in (ng/mL) / mg rapamycin). While substantial inter-individual heterogeneity in blood rapamycin levels was observed for both formulations, repeat tests for individuals demonstrated high test-retest reliability. As we detected no significant association between bioavailability and measures of body mass index (BMI), sex, age, or length of time taking rapamycin, we suggest that individualized dosing and routine monitoring of blood rapamycin levels should be applied to ensure optimal longevity efficacy. Finally, we contextualize our data with a brief review of the literature on the currently available knowledge of rapamycin’s bioavailability in normative aging populations, and provide implications for the clinical use of rapamycin in longevity medicine moving forward.Competing Interest StatementGH, VL, AN, MM, BV, CT, SLM, AI, and SZ are employees and shareholders of AgelessRx. MW and JH have received financial compensation from AgelessRx for their contributions. KK is an employee and shareholder of Venture Plant AB and Rapamycin Longevity Lab, which has received a donation from AgelessRx for research coordination in partnership with Ora Biomedical.Clinical TrialNCT06550271Funding StatementThis study was funded by AgelessRx.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM, approval number IRCM-2022-352) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors